889 reports of this reaction
2.2% of all INSULIN GLARGINE YFGN reports
#5 most reported adverse reaction
HYPERGLYCAEMIA is the #5 most commonly reported adverse reaction for INSULIN GLARGINE YFGN, manufactured by Biocon Biologics Inc.. There are 889 FDA adverse event reports linking INSULIN GLARGINE YFGN to HYPERGLYCAEMIA. This represents approximately 2.2% of all 39,886 adverse event reports for this drug.
Patients taking INSULIN GLARGINE YFGN who experience hyperglycaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERGLYCAEMIA is a less commonly reported adverse event for INSULIN GLARGINE YFGN, but still significant enough to appear in the safety profile.
In addition to hyperglycaemia, the following adverse reactions have been reported for INSULIN GLARGINE YFGN:
The following drugs have also been linked to hyperglycaemia in FDA adverse event reports:
HYPERGLYCAEMIA has been reported as an adverse event in 889 FDA reports for INSULIN GLARGINE YFGN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERGLYCAEMIA accounts for approximately 2.2% of all adverse event reports for INSULIN GLARGINE YFGN, making it a notable side effect.
If you experience hyperglycaemia while taking INSULIN GLARGINE YFGN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.